Fiscal Year:
2002
Title:
COMBINATORIAL BIOSYNTHESIS OF NOVEL BIOREDUCTIVE AGENTS
Agency:
HHS
Contract:
1R43GM062691-01A2
Award Amount:
$148,400.00
Abstract:
DESCRIPTION (provided by applicant): The structural and biosynthetic similaritybetween FR900482 and mitomycin (MC) group of antitumor antibiotics makes it
promising to rationally create novel mitomycin/FR900482 hybrids through
combinatorial biosynthesis. After successful identification of both MC and
FR900482 biosynthetic gene clusters, Acera Biosciences now sets to create such
potent bioreductive agents through manipulating these pathways. The long-term
goal is to generate large libraries of novel hybrids to eventually find
compounds with increased tumor specificity and reduced systemic toxicity. The
specific aims in this project include 1). Production of novel C6 methyl
FR900482 derivatives by MC carbonyl reduction enzyme Mmcl. 2). Creation of
novel chimeric MC/FR900482 hybrids. 3). Development of a multiplasmid system
for further biosynthetic pathway design. Dozens of novel MC/FR900482 hybrids
are expected to be generated in this proposal. The compounds with MC quinone
and FR900482 hemiketal functions will be of special interests for making more
potent anticancer agents.
Business Contact:
David Taus
9524754929
Small Business Information at Submission:
ACERA BIOSCIENCES, INC.
ACERA BIOSCIENCES, INC. 603 E LAKE ST, STE 200F WAYZATA, MN 55391
EIN/Tax ID:
411944324
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No